Saving Lives from Opioid Overdoses: Naloxone Policy Discussion and Training

The Cato Institute
01:35:40 Report Issue
Loading transcript... Click for full transcript

Chapters & Sections (66)

0:00 Opioid Overdose Prevention and Treatment Discussion chapter 3
0:00 Opioid Overdose Prevention and Treatment Discussion
2:22 David Hyman's Academic Background and Experience
3:45 Naloxone and Opioid Receptors Explained
6:15 Naloxone Administration and Opioid Overdose Reversal chapter 3
6:15 Naloxone Administration and Opioid Overdose
7:55 Suboxone Mechanism of Action Explained
9:25 Opioid Overdose Treatment and Withdrawal Symptoms
10:52 Naloxone Availability and Overdose Prevention chapter 2
10:52 Naloxone Availability and Overdose Prevention
13:09 State Health Director Issues Standing Order
15:11 Naloxone Accessibility and Stigma chapter 3
15:11 Naloxone Accessibility and Stigma Reduction
17:25 Naloxone Availability and Opioid Use Disorder
18:49 Vending Machines for Narcan Sales
21:47 FDA Criteria for Over-the-Counter Medications chapter 2
21:47 Over-the-Counter vs Prescription Drug Purchasing
23:42 Naloxone Switch to Over-the-Counter Discussion
26:01 Naloxone Over-the-Counter Availability Hurdles chapter 2
26:01 Naloxone Over-the-Counter Treatment Discussion
28:06 Regulatory Framework for Naloxone Availability
30:34 Rural Access to Over-the-Counter Narcan chapter 3
30:34 Rural Access to Medication
32:06 Accessibility of Medication in Retail Establishments
34:09 Moral Hazard in Opioid Overdose Prevention
35:47 Manufacturers' Incentives for Over-the-Counter Naloxone chapter 3
35:47 Manufacturers' Incentives for Over-the-Counter Naloxone
37:48 Criticism of Cato Institute's Funding
39:16 Opioid Overdose Prevention and Response Strategies
42:36 History of Opioids and Overdose Statistics chapter 3
42:36 History and Statistics of Opioid Overdoses
44:19 Fentanyl Analogues and Opioid Overdose Risks
45:35 Protecting Against Fentanyl Exposure Myths
47:08 Recognizing Opioid Overdose Symptoms and Risks chapter 2
47:08 Opioid Overdose Signs and Risk Factors
48:47 Opioid Overdose Risks and Warning Signs
51:17 Opioid Prescribing Guidelines and Prevention chapter 3
51:17 Opioid Prescribing Guidelines and Prevention
53:50 Opioid Treatment and Overdose Prevention Efforts
55:10 Opioid Overdose Prevention and Narcan Distribution
56:49 Narcan Use in High-Risk Situations chapter 3
56:49 De-escalation in High-Risk Situations
58:11 Naloxone Access and Administration Discussion
1:00:08 Project Lazarus and Harm Reduction Programs
1:01:54 Naloxone Law and Good Samaritan Protection chapter 2
1:01:54 Naloxone Law and Good Samaritan Protection
1:03:41 Good Samaritan Law and Fentanyl Testing
1:06:20 Opioid Overdose Trends in Washington D.C. chapter 5
1:06:20 Opioid Overdose Trends in Washington DC
1:08:15 Opioid Overdose Deaths in DC from 2014-2018
1:09:38 Opioid Overdose Deaths in DC Jurisdiction
1:11:37 Opioid Overdose Trends in Washington D.C.
1:13:30 Opioid Overdose Response and Misconceptions
1:15:08 Assessing Unresponsive Person for Breathing chapter 5
1:15:08 Assessing Unresponsive Individuals for Breathing
1:16:45 Heroin Overdose Response and Narcan Administration
1:18:18 Overdose Response and Rescue Breathing Techniques
1:20:26 Narcan Administration and Post-Overdose Care
1:22:18 Overdose Response and Community Support
1:24:14 Naloxone Availability and Overdose Prevention chapter 2
1:24:14 Naloxone Distribution and Overdose Prevention
1:26:32 Administering Narcan Nasal Spray Instructions
1:28:40 Administering Narcan in Overdose Situations chapter 3
1:28:40 Narcan Administration and Overdose Response
1:30:32 Narcan Distribution and Emergency Medical Treatment
1:33:04 Access to Narcan in the Community

Transcript

Loading transcript...